Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMiguel Martín, Noelia Jáñez Martínez, Beverly Moy et al.|The Lancet Oncology|2017Cited by 594
A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT)David M. Brizel, Bin Yao, Terence S. Herman et al.|International Journal of Radiation Oncology*Biology*Physics|2001Cited by 22